Paper36969852
The current trend of exosome in epithelial ovarian cancer studies: A bibliometric review.
Baghban N and 2 others. Front Pharmacol, 2023. Cited by 12 papers, by iCite.
Cite this record
ConductScience Library. The current trend of exosome in epithelial ovarian cancer studies: A bibliometric review. Papers, record 36969852. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36969852
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The current trend of exosome in epithelial ovarian cancer studies: A bibliometric review.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References94
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34680550 | Circulating Exosomal miRNAs as Biomarkers in Epithelial Ovarian Cancer. | Biomedicines | 2021 | https://conductscience.org/library/papers/34680550 | PubMed |
| 2 | 33627627 | Exosomes in ovarian cancer ascites promote epithelial-mesenchymal transition of ovarian cancer cells by delivery of miR-6780b-5p. | Cell Death Dis | 2021 | https://conductscience.org/library/papers/33627627 | PubMed |
| 3 | 33910598 | Plasma-derived exosomal miR-4732-5p is a promising noninvasive diagnostic biomarker for epithelial ovarian cancer. | J Ovarian Res | 2021 | https://conductscience.org/library/papers/33910598 | PubMed |
| 4 | 35003018 | Algal Cells-Derived Extracellular Vesicles: A Review With Special Emphasis on Their Antimicrobial Effects. | Front Microbiol | 2021 | https://conductscience.org/library/papers/35003018 | PubMed |
| 5 | 32326768 | microRNAs as biomarkers of ovarian cancer. | Expert Rev Anticancer Ther | 2020 | https://conductscience.org/library/papers/32326768 | PubMed |
| 6 | 26181817 | Elevated Abundance, Size, and MicroRNA Content of Plasma Extracellular Vesicles in Viremic HIV-1+ Patients: Correlations With Known Markers of Disease Progression. | J Acquir Immune Defic Syndr | 2015 | https://conductscience.org/library/papers/26181817 | PubMed |
| 7 | 30669512 | Extracellular Vesicle-Mediated Cell⁻Cell Communication in the Nervous System: Focus on Neurological Diseases. | Int J Mol Sci | 2019 | https://conductscience.org/library/papers/30669512 | PubMed |
| 8 | 34298602 | Extracellular Vesicle Transmission of Chemoresistance to Ovarian Cancer Cells Is Associated with Hypoxia-Induced Expression of Glycolytic Pathway Proteins, and Prediction of Epithelial Ovarian Cancer Disease Recurrence. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34298602 | PubMed |
| 9 | 30585260 | Exosomal Metastasis‑Associated Lung Adenocarcinoma Transcript 1 Promotes Angiogenesis and Predicts Poor Prognosis in Epithelial Ovarian Cancer. | Int J Biol Sci | 2018 | https://conductscience.org/library/papers/30585260 | PubMed |
| 10 | 30864689 | Proteomics profiling of plasma exosomes in epithelial ovarian cancer: A potential role in the coagulation cascade, diagnosis and prognosis. | Int J Oncol | 2019 | https://conductscience.org/library/papers/30864689 | PubMed |
| 11 | 35871126 | IL-6 secretion of CD4+ T cells stimulated by LC3-positive extracellular vesicles in human epithelial ovarian cancer. | Clin Transl Oncol | 2022 | https://conductscience.org/library/papers/35871126 | PubMed |
| 12 | 25579119 | The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells. | Gynecol Oncol | 2015 | https://conductscience.org/library/papers/25579119 | PubMed |
| 13 | 19622511 | Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. | Ann Intern Med | 2009 | https://conductscience.org/library/papers/19622511 | PubMed |
| 14 | 31839712 | miR-139 Controls Viability Of Ovarian Cancer Cells Through Apoptosis Induction And Exosome Shedding Inhibition By Targeting ATP7A. | Onco Targets Ther | 2019 | https://conductscience.org/library/papers/31839712 | PubMed |
| 15 | 35025082 | Anti-lung Cancer Marine Compounds: A Review. | Ther Innov Regul Sci | 2022 | https://conductscience.org/library/papers/35025082 | PubMed |
| 16 | 24102732 | Prognostic significance of thrombocytosis, platelet parameters and aggregation rates in epithelial ovarian cancer. | J Obstet Gynaecol Res | 2014 | https://conductscience.org/library/papers/24102732 | PubMed |
| 17 | 35414084 | The implications of exosomes in pregnancy: emerging as new diagnostic markers and therapeutics targets. | Cell Commun Signal | 2022 | https://conductscience.org/library/papers/35414084 | PubMed |
| 18 | 30770776 | Macrophages derived exosomes deliver miR-223 to epithelial ovarian cancer cells to elicit a chemoresistant phenotype. | J Exp Clin Cancer Res | 2019 | https://conductscience.org/library/papers/30770776 | PubMed |
| 19 | 30959137 | Expression of CD24 in plasma, exosome and ovarian tissue samples of serous ovarian cancer patients. | J Biotechnol | 2019 | https://conductscience.org/library/papers/30959137 | PubMed |
| 20 | 28216373 | TWEAK-stimulated macrophages inhibit metastasis of epithelial ovarian cancer via exosomal shuttling of microRNA. | Cancer Lett | 2017 | https://conductscience.org/library/papers/28216373 | PubMed |
Cited by8
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 12 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40786044 | Critical dysregulated signaling pathways in drug resistance: highlighting the repositioning of mebendazole for cancer therapy. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/40786044 | PubMed |
| 40207548 | Past, present, and future of exosomes research in cancer: A bibliometric and visualization analysis. | Hum Vaccin Immunother | 2025 | https://conductscience.org/library/papers/40207548 | PubMed |
| 39950738 | Exosomes in the Chemoresistance of Glioma: Key Point in Chemoresistance. | J Cell Mol Med | 2025 | https://conductscience.org/library/papers/39950738 | PubMed |
| 39048891 | Knowledge mapping of exosomes in prostate cancer from 2003 to 2022: a bibliometric analysis. | Discov Oncol | 2024 | https://conductscience.org/library/papers/39048891 | PubMed |
| 38473244 | Advances in 3D Culture Models to Study Exosomes in Triple-Negative Breast Cancer. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38473244 | PubMed |
| 38391160 | Research prospects for kidney xenotransplantation: a bibliometric analysis. | Ren Fail | 2024 | https://conductscience.org/library/papers/38391160 | PubMed |
| 38111527 | Application of medical imaging in ovarian cancer: a bibliometric analysis from 2000 to 2022. | Front Oncol | 2023 | https://conductscience.org/library/papers/38111527 | PubMed |
| 37475778 | Role of CD9 Sensing, AI, and Exosomes in Cellular Communication of Cancer. | Int J Stem Cell Res Ther | 2023 | https://conductscience.org/library/papers/37475778 | PubMed |
Genes17
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36969852
GET https://conductscience.org/api/papers/v1/36969852/references?page=2